Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells

19 Jun 2020

Abstract excerpt

This overview summarizes recent data disclosing the efficacy of the PARP inhibitor PJ34 in exclusive eradication of a variety of human cancer cells without impairing healthy proliferating cells. Its cytotoxic activity in cancer cells is attributed to the insertion of specific un-repairable anomalies in the structure of their mitotic spindle, leading to mitotic catastrophe cell death. This mechanism paves the way...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32575437
DOI: 10.3390/cancers12061628

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer CellsPMID 32575437Read ↗

A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cellsSemantic proximity Read ↗

A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitorsSemantic proximity Read ↗

Mitosis-targeted anti-cancer therapies: where they standSemantic proximity Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in CancerSemantic proximity Read ↗

Mitotic Poisons in Research and MedicineSemantic proximity Read ↗

Targeting Microtubules by Natural Agents for Cancer TherapySemantic proximity Read ↗

Development of anticancer drugs based on the hallmarks of tumor cells.Semantic proximity Read ↗

DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventionsSemantic proximity Read ↗

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.Semantic proximity Read ↗

Mitotic Poisons In Cancer PharmacotherapySemantic proximity Read ↗

Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.